Racura Oncology Ltd has released a press release.
CPACS Trial Opens for RC220 Patient Enrolment in Korea
Earlier from Racura Oncology
- First HARNESS-1 Patient Safely Treated with RC220
- June 2026 Quarterly Activities Report and Appendix 4C
- Bellberry Ethics Approval Activates New HARNESS Trial Sites
- Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer